281 related articles for article (PubMed ID: 32615068)
1. Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy.
Innamarato P; Kodumudi K; Asby S; Schachner B; Hall M; Mackay A; Wiener D; Beatty M; Nagle L; Creelan BC; Sarnaik AA; Pilon-Thomas S
Mol Ther; 2020 Oct; 28(10):2252-2270. PubMed ID: 32615068
[TBL] [Abstract][Full Text] [Related]
2. Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy.
Innamarato P; Pilon-Thomas S
Cell Immunol; 2021 Mar; 361():104277. PubMed ID: 33476931
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
4. Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
Bazargan S; Bunch B; Ojwang' AME; Blauvelt J; Landin A; Ali J; Abrahams D; Cox C; Hall AM; Beatty MS; Poch M; Rejniak KA; Pilon-Thomas S
Front Immunol; 2023; 14():1275375. PubMed ID: 37901214
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.
Santos JM; Cervera-Carrascon V; Havunen R; Zafar S; Siurala M; Sorsa S; Anttila M; Kanerva A; Hemminki A
Mol Ther; 2018 Sep; 26(9):2243-2254. PubMed ID: 30017877
[TBL] [Abstract][Full Text] [Related]
6. The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.
Luker AJ; Graham LJ; Smith TM; Camarena C; Zellner MP; Gilmer JS; Damle SR; Conrad DH; Bear HD; Martin RK
BMC Immunol; 2020 Feb; 21(1):8. PubMed ID: 32106810
[TBL] [Abstract][Full Text] [Related]
7. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
8. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Dudley ME; Yang JC; Sherry R; Hughes MS; Royal R; Kammula U; Robbins PF; Huang J; Citrin DE; Leitman SF; Wunderlich J; Restifo NP; Thomasian A; Downey SG; Smith FO; Klapper J; Morton K; Laurencot C; White DE; Rosenberg SA
J Clin Oncol; 2008 Nov; 26(32):5233-9. PubMed ID: 18809613
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.
Wallen H; Thompson JA; Reilly JZ; Rodmyre RM; Cao J; Yee C
PLoS One; 2009; 4(3):e4749. PubMed ID: 19270751
[TBL] [Abstract][Full Text] [Related]
10. Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?
Muranski P; Boni A; Wrzesinski C; Citrin DE; Rosenberg SA; Childs R; Restifo NP
Nat Clin Pract Oncol; 2006 Dec; 3(12):668-81. PubMed ID: 17139318
[TBL] [Abstract][Full Text] [Related]
11. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
[TBL] [Abstract][Full Text] [Related]
12. Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the
Kobayashi M; Chung JS; Beg M; Arriaga Y; Verma U; Courtney K; Mansour J; Haley B; Khan S; Horiuchi Y; Ramani V; Harker D; Gopal P; Araghizadeh F; Cruz PD; Ariizumi K
Clin Cancer Res; 2019 Jan; 25(2):828-838. PubMed ID: 30049749
[TBL] [Abstract][Full Text] [Related]
13. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.
Rohaan MW; van den Berg JH; Kvistborg P; Haanen JBAG
J Immunother Cancer; 2018 Oct; 6(1):102. PubMed ID: 30285902
[TBL] [Abstract][Full Text] [Related]
14. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy.
Nissani A; Lev-Ari S; Meirson T; Jacoby E; Asher N; Ben-Betzalel G; Itzhaki O; Shapira-Frommer R; Schachter J; Markel G; Besser MJ
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33990415
[TBL] [Abstract][Full Text] [Related]
15. Principles of adoptive T cell therapy in cancer.
Met Ö; Jensen KM; Chamberlain CA; Donia M; Svane IM
Semin Immunopathol; 2019 Jan; 41(1):49-58. PubMed ID: 30187086
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of adoptive immunotherapy and docetaxel inhibits tumor growth in a mouse model.
Hu Y; Liu J; Cui P; Liu T; Piao C; Xu X; Zhang Q; Xiao M; Lu Y; Liu X; Wang Y; Lu X
Cell Immunol; 2020 Feb; 348():104036. PubMed ID: 31924315
[TBL] [Abstract][Full Text] [Related]
17. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
Mayor P; Starbuck K; Zsiros E
Gynecol Oncol; 2018 Aug; 150(2):361-369. PubMed ID: 29803316
[TBL] [Abstract][Full Text] [Related]
18. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
Kumar A; Watkins R; Vilgelm AE
Front Immunol; 2021; 12():690499. PubMed ID: 34140957
[TBL] [Abstract][Full Text] [Related]
19. Key Factors in Clinical Protocols for Adoptive Cell Therapy in Melanoma.
Considine B; Hurwitz ME
Methods Mol Biol; 2020; 2097():309-327. PubMed ID: 31776935
[TBL] [Abstract][Full Text] [Related]
20. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Dudley ME; Somerville R; Wunderlich JR; Sherry RM; Yang JC; Rosenberg SA; Kammula US
Clin Cancer Res; 2015 Feb; 21(3):534-43. PubMed ID: 25424856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
